Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-08-25 00:00:00 ET · period of report 2023-08-23 · accession 0001968202-23-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-25 | 2023-08-23 | REGN | Landry Robert E | EVP Fin CFO | S - Sale | $844.00 | -223 | 31.7K | -0.7% | -$188.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-23 | S | D | 223 | $844.00 | 31,699 | D | — | — |